The Mexican government announced a combined investment of approximately 12.25 billion pesos (around 643 million U.S. dollars) by four pharmaceutical companies—Boehringer Ingelheim, Carnot Laboratorios, Bayer, and AstraZeneca—as part of the Plan México initiative. This investment aims to expand local production capacities, modernize manufacturing infrastructure, and strengthen national health sovereignty by boosting the local manufacture of essential medicines. The projects will be implemented across several states including Mexico City, Estado de México, Jalisco, Veracruz, Tlaxcala, and Hidalgo. AstraZeneca alone plans to invest 2 billion pesos focusing on research development, job creation, and expanding its manufacturing site in Estado de México. Bayer will contribute 3 billion pesos over five years to modernize and expand operations in health, agriculture, and science sectors. The investments are expected to generate over 3,000 jobs, enhance the country’s preparedness for future pandemics, and support the development of high-specialty employment. Mexican officials, including Secretary of Health David Kershenobich and Secretary Marcelo Ebrard, emphasized the confidence of both national and international pharmaceutical industries in Mexico's economic environment. The announcement was made during the Mañanera del Pueblo press conference led by President Claudia Sheinbaum, highlighting the government's commitment to economic development and health sector strengthening.